About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Use of Baricitenib to Maintain of Remission | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 2/3NCT05686746

Use of Baricitenib to Maintain of Remission

Baricitinib a selective Janus kinase (JAK) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated eff...

Lead sponsor: Assiut University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Manal Hassanien, MD

CONTACT

00201062679200 manal_hassanien@yahoo.com

Sponsors

Lead Sponsor

Assiut University

Baricitinib a selective Janus kinase (JAK) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date. Objectives: To assess the efficacy and safety of Baricitinib in patients (pts) with LN by dose 4mg versus 2 mg versus MMF 1 gm daily dose.

Age

20 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Clinical diagnosis of Lupus nephritis Disease
•Must be able to swallow tablets
•lupus nephritis in remission

Exclusion Criteria

•antiphospholipid syndrome disease
•thrombosis history
•sever anemia, leukopenia or thrombocytopenia
•impaired liver and renal function

Related studies

RECRUITINGPhase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

NCT00977977 · Nephrotic Syndrome, Proteinuria, and more

RECRUITINGPhase 1/2

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363 · Autoimmune Disorders, Systemic Sclerosis, and more

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

NCT05996731 · Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and more

RECRUITINGPhase 2

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

NCT05538208 · Lupus Nephritis

RECRUITINGPhase 3

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277 · Lupus Nephritis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 17, 2023Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2/PHASE3

Enrollment80

Start dateJun 2022

Last updatedJan 17, 2023

Condition

Lupus or SLE Nephritis

Locations shown

Manal Hassanien

Asyut, Yes

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 17, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions